Dr Lal PathLabs Targets 27% Margin In FY26, Plans To Foray Into New Regions
NDTV Profit
The company aims to open 15 to 20 labs in this fiscal, while expanding its network in southern and western states.
Geojit BNP Paribas increased Hold price target of Dr. Lal Pathlabs Ltd. to 3548.0 on 02 Sep, 2025.
854.00
1.15%
Business Line
The upswing that followed has taken the stock above a notable resistance at 840 and both 20- and 50-day moving averages, turning the short-term outlook bullish
Natco Pharma Ltd. is trading below all available SMAs
854.00
1.15%
Business Line
Will NATCO Pharma's stock trend this week?
Number of FII/FPI investors decreased from 385 to 317 in Jun 2025 qtr
750.75
-0.07%
IndusInd may slip into red in Q4 on derivative losses
Economic Times
On Sunday evening, IndusInd confirmed it would fully absorb the derivatives-related loss this quarter, following the conclusion of a board-mandated investigation into accounting irregularities in internal derivative transactions.